Daejeon, South Korea

Mi Hong Min


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Mi Hong Min in Nanoparticle Compositions

Introduction

Mi Hong Min is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceutical compositions, particularly focusing on the development of nanoparticle formulations for oral administration. His work aims to enhance the effectiveness of water-soluble drugs through innovative delivery methods.

Latest Patents

Mi Hong Min holds a patent for "Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof." This invention relates to an orally administrable composition containing nanoparticles with a particle size of 500 nm or less. The composition comprises 0.1-30 weight % of a complex of a water-soluble drug and a counter-ion substance, 0.5-80 weight % of a lipid, 0.5-80 weight % of a polymer, and 1-80 weight % of an emulsifier. The formulation is designed to achieve a high gastrointestinal absorption rate upon oral administration, a high drug entrapping rate in the nanoparticle, and stability against lipases. Mi Hong Min has 1 patent to his name.

Career Highlights

Mi Hong Min is currently employed at Samyang Corporation, where he continues to innovate in the field of drug delivery systems. His work is pivotal in advancing the pharmaceutical industry, particularly in improving the bioavailability of medications.

Collaborations

Mi Hong Min collaborates with talented colleagues, including Chaul Min Pai and Jun Seok Hwang. Their combined expertise contributes to the success of their projects and the advancement of their research.

Conclusion

Mi Hong Min's contributions to nanoparticle compositions represent a significant advancement in the field of pharmaceuticals. His innovative approach to drug delivery systems has the potential to improve patient outcomes and enhance the effectiveness of oral medications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…